KOL Insight - Chronic Obstructive Pulmonary Disease

This report provides an in-depth analysis of the evolving landscape of chronic obstructive pulmonary disease (COPD) treatment, highlighting the increasing use of fixed-dose triple combination therapies and the introduction of biologics like Dupixent and Nucala. Gain insights into how these therapies are being integrated into treatment regimens for severe COPD patients and the implications of recent clinical trial results. The report also discusses the impact of new biologic therapies on the market, offering a detailed analysis of current trends and future directions in COPD management for pharmaceutical professionals.

Key Questions Answered:

• What factors influence the uptake of triple therapies for COPD in the US and Europe?
• How are triple therapies used across different patient populations?
• Can Trimbow's Phase III TRITON study lead to US approval and market success?
• What is the clinical impact of Breztri/Trixeo's Phase III KRONOS data?
• How significant is Dupixent's approval for COPD, and what market share can it capture?
• What are the approval prospects and competitive landscape for Nucala and Fasenra in COPD treatment?

Key Brands:

Partial List of Participating Experts:

• Professor of Medicine at Harvard Medical School and attending physician at Brigham and Women's Hospital, Boston, MA, US
• Professor of Medicine and Director of Research, Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD, US
• Chair and Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, US
• Professor and Consultant, Department of Pneumology, University Hospital Vall d'Hebron, Barcelona, Spain
• Professor, Division of Infection, Immunity & Respiratory Medicine, University of Manchester, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
• Professor of Respiratory Medicine at Paris Cite University and Head of the Department of Respiratory Medicine, Cochin Hospital, APHP Centre, Paris, France

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.